

Summary Public Assessment Report

Empagliflozin Devatis (empagliflozin)

SE/H/2553/01-02/DC

Summary Public Assessment Report

Empagliflozin Devatis
empagliflozin

Film-coated tablet, 10 mg, 25 mg

This is a summary of the public assessment report (PAR) for Empagliflozin Devatis. It explains how the assessment was made and why the authorisation was recommended as well as the conditions of use. It is not intended to provide practical advice on how to use the product.

For practical information about the use of the product, patients should read the package leaflet or contact their doctor or pharmacist.

What is Empagliflozin Devatis and what is it used for?

The product is a 'generic medicine'. This means that it is similar to a 'reference medicine' already authorised in the European Union (EU) called Jardiance.

The product is used in the treatment of type 2 diabetes in adults and children aged 10 years and older that cannot be controlled by diet and exercise alone.

How does Empagliflozin Devatis work?

The product works by blocking the SGLT2 protein in your kidneys. This causes blood sugar (glucose) to be removed in your urine. Thereby, the product lowers the amount of sugar in your blood. This medicine can also help prevent heart disease in patients with type 2 diabetes mellitus.

How is Empagliflozin Devatis used?

The pharmaceutical form is film-coated tablet for oral use.

Please read section 3 of the package leaflet for detailed information on dosing recommendations, the route of administration, and the duration of treatment.

The medicine can only be obtained with a prescription in Sweden.

What benefits of Empagliflozin Devatis have been shown in studies?

Because the product is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Jardiance. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

What are the possible side effects from Empagliflozin Devatis?

Because the product is a generic medicine, its benefits and possible side effects are taken as being the same as the reference medicine.

For the full list of side effects, see section 4 of the package leaflet.

For the full list of restrictions, see the package leaflet.

Why is Empagliflozin Devatis approved?

It was concluded that, in accordance with EU requirements, the product has been shown to have comparable quality and is considered to be bioequivalent to the reference medicine. Therefore, the Swedish Medical Products Agency decided that, as for Jardiance, the benefits are greater than its risks and recommended that it can be approved for use.

What measures are being taken to ensure the safe and effective use of Empagliflozin Devatis?

A risk management plan has been developed to ensure that the product is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet, including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously as well.

Other information about Empagliflozin Devatis

The full PAR for Empagliflozin Devatis can be found on the following website: [MRI - Home](#). For more information about treatment with Empagliflozin Devatis, please read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in 2025-06.